[go: up one dir, main page]

DE60114018D1 - Von zellen präsentierte peptide - Google Patents

Von zellen präsentierte peptide

Info

Publication number
DE60114018D1
DE60114018D1 DE60114018T DE60114018T DE60114018D1 DE 60114018 D1 DE60114018 D1 DE 60114018D1 DE 60114018 T DE60114018 T DE 60114018T DE 60114018 T DE60114018 T DE 60114018T DE 60114018 D1 DE60114018 D1 DE 60114018D1
Authority
DE
Germany
Prior art keywords
peptides
determination
relates
present
presented peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60114018T
Other languages
English (en)
Other versions
DE60114018T2 (de
Inventor
J Carr
Graham Carter
Koen Hellendoorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE60114018D1 publication Critical patent/DE60114018D1/de
Application granted granted Critical
Publication of DE60114018T2 publication Critical patent/DE60114018T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • G01N33/6851Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60114018T 2000-08-03 2001-07-26 Von zellen präsentierte peptide Expired - Lifetime DE60114018T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
GB0018901 2000-08-03
PCT/EP2001/008625 WO2002012899A2 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Publications (2)

Publication Number Publication Date
DE60114018D1 true DE60114018D1 (de) 2006-02-23
DE60114018T2 DE60114018T2 (de) 2006-06-29

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60114018T Expired - Lifetime DE60114018T2 (de) 2000-08-03 2001-07-26 Von zellen präsentierte peptide

Country Status (20)

Country Link
US (1) US20030171290A1 (de)
EP (1) EP1305343B1 (de)
JP (1) JP2004506202A (de)
KR (1) KR20030037272A (de)
CN (1) CN1511164A (de)
AT (1) ATE306498T1 (de)
AU (1) AU2001283958A1 (de)
BR (1) BR0112925A (de)
CA (1) CA2417767A1 (de)
CZ (1) CZ2003464A3 (de)
DE (1) DE60114018T2 (de)
GB (1) GB0018901D0 (de)
HU (1) HUP0301581A2 (de)
MX (1) MXPA03000901A (de)
NO (1) NO20030495L (de)
PL (1) PL358874A1 (de)
RU (1) RU2003105806A (de)
SK (1) SK1982003A3 (de)
WO (1) WO2002012899A2 (de)
ZA (1) ZA200301637B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292778A1 (en) * 2000-09-18 2002-03-26 Genzyme Corporation Method to identify therapeutic antibody targets associated with a therapeutic response
US20040235062A1 (en) * 2001-06-19 2004-11-25 Terumi Nakajima Method of analyzing protein occurring in cell or substance interacting with the protein
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク. 複合ワクチン
DK1673398T3 (da) 2003-10-16 2011-04-18 Micromet Ag Multispecifikke, deimmuniserede CD3-bindere
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (de) 2007-07-03 2016-05-25 Dako Denmark A/S Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
KR20120104558A (ko) 2009-11-05 2012-09-21 세파론 오스트레일리아 피티와이 엘티디 돌연변이형 kras 또는 braf 유전자를 포함하는 암을 치료하는 방법
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
EP2997133B1 (de) * 2013-05-13 2023-08-23 Cellectis Verfahren zur züchtung hochaktiver t-zellen zur immuntherapie
CN119905147A (zh) 2015-12-16 2025-04-29 磨石生物公司 新抗原的鉴别、制造及使用
EP3356522A4 (de) * 2016-09-30 2019-03-27 Cellex Life Sciences, Incorporated Zusammensetzungen mit proteinbeladenem exosom und verfahren zur herstellung und freisetzung davon
EP4576103A2 (de) 2017-10-10 2025-06-25 Gritstone bio, Inc. Neoantigenidentifizierung mit hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0983303B1 (de) * 1997-05-21 2006-03-08 Biovation Limited Verfahren zur herstellung von nicht-immunogenen proteinen
ES2278463T3 (es) * 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US6468537B1 (en) * 1999-04-28 2002-10-22 The Board Of Trustees Of Northwestern University Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
GB0018901D0 (en) 2000-09-20
PL358874A1 (en) 2004-08-23
CN1511164A (zh) 2004-07-07
ZA200301637B (en) 2004-02-03
ATE306498T1 (de) 2005-10-15
NO20030495D0 (no) 2003-01-31
JP2004506202A (ja) 2004-02-26
HUP0301581A2 (hu) 2003-08-28
WO2002012899A3 (en) 2002-11-07
WO2002012899A2 (en) 2002-02-14
MXPA03000901A (es) 2003-06-24
CZ2003464A3 (cs) 2003-06-18
AU2001283958A1 (en) 2002-02-18
SK1982003A3 (en) 2003-08-05
KR20030037272A (ko) 2003-05-12
CA2417767A1 (en) 2002-02-14
EP1305343B1 (de) 2005-10-12
US20030171290A1 (en) 2003-09-11
BR0112925A (pt) 2003-08-26
RU2003105806A (ru) 2004-07-20
EP1305343A2 (de) 2003-05-02
NO20030495L (no) 2003-01-31
DE60114018T2 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
DE60114018D1 (de) Von zellen präsentierte peptide
Qin et al. Identification and characterization of posttranslational modifications of proteins by MALDI ion trap mass spectrometry
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1111006T1 (el) Εκριμματαση ασθενειας alzheimer
BR0211200A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
BR0009206A (pt) Isolamento e análise de proteina
WO2002002783A3 (en) Expression vectors
WO2004024750A3 (en) Cd44-binding ligands
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2006069203A3 (en) Methods for proteomic profiling using non-natural amino acids
DE60034966D1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
WO2001053531A3 (en) Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
ATE356207T1 (de) Humanes btrcp protein
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
PL374550A1 (en) Il-17 like molecules and uses thereof
SE9701228D0 (sv) Rekombinanta protein-C-och protein-S-varianter
WO2004050870A3 (en) Genetic switches for the detection of fusion proteins
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
BRPI0308978B8 (pt) fragmentos de peptídeos, e, composições imunogênicas
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
ATE338764T1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition